A state-wide initiative to promote genetic testing in an underserved population

Meghan L. Underhill
Dana-Farber Cancer Institute

Let us know how access to this document benefits you. Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Community Health and Preventive Medicine Commons, Diagnosis Commons, Genetics Commons, Health Services Administration Commons, Investigative Techniques Commons, Medical Genetics Commons, Neoplasms Commons, and the Oncology Commons

Repository Citation
Underhill ML, Blonquist TM, Habin K, Lundquist D, Shannon K, Robinson K, Woodford M, Boucher J. (2017). A state-wide initiative to promote genetic testing in an underserved population. Open Access Publications by UMMS Authors. https://doi.org/10.1002/cam4.1100. Retrieved from https://escholarship.umassmed.edu/oapubs/3144

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
A state-wide initiative to promote genetic testing in an underserved population

Meghan L. Underhill1, Traci M. Blonquist1, Karleen Habin2,5, Debra Lundquist3,5, Kristen Shannon2, Kathryn Robinson4, Mary-Lou Woodford5 & Jean Boucher6,1

1Dana-Farber Cancer Institute, 450 Brookline Ave LW522, Boston, Massachusetts, 02115
2Massachusetts General Hospital, Boston, MA, USA
3Boston College, Connell School of Nursing, Cancer Resource Foundation, Chestnut Hill, MA, USA
4School of Nursing, Northeastern University, Boston, MA, USA
5Cancer Resource Foundation, Marlborough, MA, USA
6Graduate School of Nursing, University of Massachusetts Medical School, Worcester, MA, USA

Keywords
Cancer, disease susceptibility, genetic testing, healthcare disparity, nursing research

Abstract
Genetic testing for cancer susceptibility has been widely studied and utilized clinically. Access to genetic services in research and practice is largely limited to well-insured, Caucasian individuals. In 2009, the Cancer Resource Foundation (CRF) implemented the Genetic Information for Treatment Surveillance and Support (GIFTSS) program to cover the out-of-pocket expenses associated with cancer genetic testing, targeting high-risk individuals with limited financial means and limited health insurance coverage. Here, we (i) describe the characteristics of participants in the Massachusetts (MA) GIFTSS program and (ii) evaluate mutations found in this diverse sample. A secondary retrospective data analysis was performed using de-identified demographic data obtained from laboratory requisition forms and cancer genetic testing result information from the laboratory source. Eligible participants were those who utilized the MA GIFTSS program from 2009 through December of 2014. Data were summarized using descriptive measures of central tendency. Participants were residents of Massachusetts who had health insurance and had a reported income within 250–400% of the federal poverty level. Genetic testing results were categorized following clinical guidelines. Overall, 123 (13%) of participants tested positive for a mutation in a cancer susceptibility gene. For those with a cancer diagnosis, 65 (12%) were found to have a positive result and 20 (7%) had a variant of uncertain significance (VUS). For those unaffected patients, 58 (15%) had a positive result and 10 (3%) were found to have a VUS. The results from this study are useful in describing genetic testing outcomes in this high-risk underserved community. Repeatedly, the literature reports that individuals from diverse or limited resource settings are less likely to access genetic testing. Continued research efforts should be devoted to promoting the access of genetic testing in the high-risk, underserved community.

Introduction
Results from cancer predisposition genetic testing are an important component of holistic cancer care and can inform treatment, diagnostic, surveillance, and preventative health recommendations [1, 2]. Patient experience and outcomes of cancer predisposition genetic testing has been widely studied, but is largely limited to well-insured, Caucasian populations with easy access to genetic counseling and testing services. Information pertaining to underserved communities is limited. Underserved communities include individuals with limited financial means, and low-socioeconomic status, who may also be racial or ethnic minorities and face barriers to genetic testing services. Thus, underserved populations remain understudied.
Costs of the genetic test and limitations to health insurance coverage are barriers to genetic testing. Cragun et al. (2015) identified that having public health insurance, with an implied limitation to coverage was a barrier to utilizing genetic testing in young black women [3]. Low household income [4], and/or low education [5] are also associated with poor uptake of genetic testing, with most data coming from BRCA1/2 gene testing. Out-of-pocket costs associated with genetic testing even in the insured have also been identified as a barrier, regardless of race or ethnicity [6]. Including individuals who are cared for in the community is a priority at the national level, though still equitable representation of diverse individuals has not yet been realized [7]. Therefore, data available related to outcomes of genetic testing in diverse and unselected populations, are often those not included in historical clinical research, and is limited.

In 2009, the Cancer Resource Foundation (CRF), a 501(c)(3) program led by oncology and public health nurse leaders, initiated the Genetic Information for Treatment Screening and Surveillance (GIFTSS) voucher program in Massachusetts (MA) to support the underinsured who could not afford the out-of-pocket expenses associated with genetic testing. Underinsured individuals were defined as those individuals who have health insurance that covers some health costs, but whose health insurance neglects to cover the entire costs of specific medical tests. This leaves these underinsured with either no access to the specific test or with a high out-of-pocket cost. At the time of inception of the program, the MA Healthcare Reform Act (HCRA), which was enacted in 2006, provided comprehensive health insurance to adults earning up to 150% of the federal poverty level. The MA HCRA did not include genetic testing as a covered service. Because individuals covered under the HCRA did have health insurance, participants in this program were not eligible for local or national financial relief programs. Thus, those individuals covered under HCRA had neither access to genetic testing as a covered benefit through their insurance nor the ability to seek outside relief programs.

The eligibility of individuals for the GIFTSS program met medical high risk as defined by the National Comprehensive Cancer Network (NCCN) [1, 2] if appropriate, and the referring clinician verified that the participant was appropriate for genetic testing. Referring clinicians were typically clinical genetic counselors, OB/GYN providers, and medical oncologists. Participants also met a financial need criterion and were considered eligible if they had a household income within or below 250–400% of the federal poverty level, and had health insurance that did not cover genetic testing. The criteria for financial inclusion was broadened from 250 to 400% to meet the needs of not only those whose insurance offered no coverage for genetic testing but also for those who did have some coverage but could not afford the out-of-pocket expenses.

The CRF relied on referring clinical experts (e.g., genetic counselors) to identify at-risk individuals who needed referral to the GIFTSS resource. The patient and provider completed the application for voucher assistance. Once completed, the provider ordered genetic testing and CRF evaluated eligibility based on financial need. Once an application is submitted, a voucher to cover the out-of-pocket costs associated with obtaining genetic testing was provided. No direct clinical care, genetic counseling, or direct (cash) reimbursement to the patient was provided as part of GIFTSS, although advanced practice nurses with expertise in cancer and genetics were available to facilitate answering questions or identifying resources as needed. Previous research conducted with a subset of participants who took part in GIFTSS had indicated that the program included a diverse group of individuals [8]. Data from our first study (N = 128) included participants from the same cohort and indicated that approximately half of the participants had a high school education or less, over half utilized state health insurance, and were from over 31 different ancestral backgrounds [8].

**Objectives**

The objectives of this analysis were to: (i) describe the characteristics of participants from the MA GIFTSS program and (ii) evaluate the types of mutations found in this sample.

**Method**

A secondary analysis of data collected from 2009 to 2014 was completed using de-identified demographic and genetic testing results obtained from the laboratory source. Partners Healthcare Institutional Review Board reviewed the protocol and determined it exempt. All data were summarized using descriptive statistics (frequency and proportion). Age at the time of genetic testing and cancer diagnosis were reported using median and range. Individuals were categorized based on gender, ancestry (as classified by the referring provider), presence or absence of a cancer diagnosis, timing of genetic testing in relation to a cancer diagnosis (before a cancer diagnosis/unaffected, at the time of diagnosis, or after cancer diagnosis), genetic testing results, and presence or absence of a reported family history of cancer. Genetic testing results were defined by three categories [9]: (i) Positive, where a deleterious gene mutation or likely deleterious mutation was identified, (ii) Uncertain, where a DNA variant of uncertain significance (VUS) or favor polymorphism (likely benign), was identified, and (iii) Negative, where no mutation was identified.
Results

Genetic testing results were available for 927 of 928 participants who took part in the voucher program. Participant characteristics are detailed in Table 1. The median age at the time of genetic testing was 46 years (range 3–86 years). Ten individuals were tested under the age of 18 (range 3–17). All minors were tested for mutations in the APC gene due to risk for Familial Adenomatous Polyposis, which is clinically indicated as standard of care [2, 10].

There were 123 (13%) individuals with gene mutations identified that were considered positive.

The family history information of the participants can be found in Table 1. For those individuals who had a cancer diagnosis, 413 (76%) also reported a first-degree relative (FDR) with cancer and for those who did not have a cancer diagnosis, 378 (98%) had a FDR with cancer. The age at time of first cancer diagnosis was known for 522 individuals. The median age at diagnosis was 44 years (range 16–78 years). The number of individuals with a cancer diagnosis who received genetic testing at the same time or after their cancer diagnosis was 508 (54%).

Participants underwent a variety of cancer genetic tests, including single-site gene testing for known family mutations, multisite gene testing, multi-gene panel, and large rearrangement testing. The genes analyzed for the cohort included: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH, CDKN2A, CDK4, TP53, PTEN, STK11, CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C, and RAD51D. Table 2 describes the name of the tests completed, the genes associated with that test, and the frequency with which the test was used in this sample. Table 3 describes the frequency of genetic tests completed and mutations detected.

The breakdown of mutations by cancer diagnosis is described in Table 4. Of those with a cancer diagnosis, 63 (12%) individuals reported more than one diagnosis of cancer. Sixty-five (12%) were found to have a deleterious or likely deleterious mutation and 20 (7%) had a VUS. For unaffected participants, 10 (3%) were found to have a VUS and 58 (15%) had a deleterious/likely deleterious mutation and of which 46 (79%) of those were found through single-site testing for a known genetic mutation within a family. Single-site gene testing (15%) was performed on 140 individuals (15%), a positive gene mutation was identified in 62 (44%) participants. Of those who underwent single-site testing, 108 individuals were unaffected.

Discussion

Here, we report individual-level genetic findings in an at-risk cohort of program participants with low-socioeconomic status in MA. Our findings demonstrate that genetic testing can provide valuable information within this community and to reach equitable genetics care, reducing barriers to accessing genetic testing should be addressed. The findings from this study should be interpreted within the sociocultural context of the multiple systems that impact genetic testing uptake, including health system, policy, and community-level factors [11]. The unmet need filled by this voucher program highlights a gap in the current health care systems ability to meet the capacity of a socially and economically diverse community.

In our sample of individuals at high risk for having a genetic predisposition to cancer who had financial need for assistance to obtain genetic testing, 42% of participants were unaffected with cancer, and of those who were...
unaffected, 98% had a first-degree relative (FDR) with cancer. Of those with a cancer diagnosis, the median age of onset was young, age 44. Therefore, our findings indicate that referral to GIFTSS was likely highly selective and that those individuals were likely appropriately referred, though this could not be confirmed. Our cohort’s testing included genes other than *BRCA1* and *BRCA2*, a focus of most research in diverse groups [12–16], making our work novel to the current state of genetic testing in routine care. A clinically actionable genetic mutation was found in 13% of our sample, while 3% had a VUS, which is consistent of rates of mutations identified in other

| Name of test | Genes included in test | N  | %  |
|---------------|------------------------|----|----|
| Myrisk        | BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH, CDKN2A, CDK4, TP53, STK11, CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D | 18 | 2  |
| BART          | BRCA1, BRCA2           | 352| 38 |
| BRCA analysis | BRCA1, BRCA2           | 554| 60 |
| Single-site BRCA1 | BRCA1           | 59 | 6  |
| Single-site BRCA2 | BRCA2           | 49 | 5  |
| Multisite    | BRCA1, BRCA2           | 24 | 3  |
| APC          | APC                    | 19 | 2  |
| Colaris      | MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH | 62 | 7  |
| Colaris AP   | MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH | 64 | 7  |
| PMS2         | PMS2                   | 59 | 6  |
| MLH1 panel   | MLH1                   | 2  | 0  |
| MSH2 panel   | MSH2                   | 3  | 0  |
| MYH          | MYH                    | 24 | 3  |
| EPCAM        | EPCAM                  | 2  | 0  |
| Single-site MLH2 | MLH1           | 4  | 0  |
| Single-site MSH2 | MSH2           | 13 | 1  |
| Single-site MSH6 | MSH6           | 5  | 1  |

### Table 2. Frequency and type of tests ordered.

| Name of test | Genes included in test | N  | %  |
|---------------|------------------------|----|----|
| Myrisk        | BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH, CDKN2A, CDK4, TP53, STK11, CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D | 18 | 2  |
| BART          | BRCA1, BRCA2           | 352| 38 |
| BRCA analysis | BRCA1, BRCA2           | 554| 60 |
| Single-site BRCA1 | BRCA1           | 59 | 6  |
| Single-site BRCA2 | BRCA2           | 49 | 5  |
| Multisite    | BRCA1, BRCA2           | 24 | 3  |
| APC          | APC                    | 19 | 2  |
| Colaris      | MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH | 62 | 7  |
| Colaris AP   | MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH | 64 | 7  |
| PMS2         | PMS2                   | 59 | 6  |
| MLH1 panel   | MLH1                   | 2  | 0  |
| MSH2 panel   | MSH2                   | 3  | 0  |
| MYH          | MYH                    | 24 | 3  |
| EPCAM        | EPCAM                  | 2  | 0  |
| Single-site MLH2 | MLH1           | 4  | 0  |
| Single-site MSH2 | MSH2           | 13 | 1  |
| Single-site MSH6 | MSH6           | 5  | 1  |

### Table 3. Number of individuals tested for a gene mutation in each gene and the results of that testing.

| Gene tested | Associated cancers or cancer syndrome | No. tested | Result | No. with findings |
|-------------|---------------------------------------|------------|--------|-------------------|
| No. of patients | - | 927 | - | 151 (16) |
| Deleterious/likely mutations | - | 123 (13) | - | - |
| APC          | Familial Adenomatous Polyposis (FAP)  | 94         | APC – Deleterious | 6 (6) |
| MYH          | MYH-associated polyposis (MAP)        | 89         | Biallelic MYH    | 1 (1) |
|             |                                       |            | Monoallelic MYH  | 5 (6) |
| BRCA1        | Hereditary Breast and Ovarian Cancer Syndrome (HBOC) | 745 | BRCA1 – Deleterious | 50 (7) |
| BRCA2        | HBOC                                  | 735        | BRCA2 – Deleterious | 45 (6) |
|             |                                       |            | BRCA2 – Likely   | 3 (<1) |
| MLH1         | Lynch Syndrome (LS)                   | 118        | MLH1 – Deleterious | 3 (2) |
| MSH2         | LS                                    | 125        | MSH2 – Deleterious | 6 (5) |
|             |                                       |            | MSH2 – Likely    | 2 (2) |
| MSH6         | LS                                    | 117        | MSH6 – Deleterious | 2 (2) |
| VUS          | -                                     | 30         | -                | 3 (3) |
| APC          | FAP                                   | 94         | APC               | 4 (4) |
| ATM          | Breast and pancreatic cancers         | 18         | ATM               | 1 (6) |
| MYH          | MAP                                   | 89         | MYH               | 2 (2) |
| BRCA1        | HBOC                                  | 745        | BRCA1             | 3 (<1) |
| BRCA2        | HBOC                                  | 735        | BRCA2             | 10 (1) |
| BRIP1        | Breast and ovarian cancers            | 18         | BRIP              | 3 (17) |
| MSH2         | LS                                    | 125        | MSH2              | 1 (<1) |
| MSH6         | LS                                    | 117        | MSH6              | 5 (4) |
| PMS2         | LS                                    | 118        | PMS2              | 3 (2) |

1. Four individuals had more than 1 mutation; two with a deleterious mutation and a VUS, and two with 2 VUS.
2. Percentage calculated from those tested.
underserved populations [14, 17, 18]. Therefore, in this sample, when financial barriers were removed, we see that this population had comparable rates of positive genetic testing results as reported in the literature.

Single-site testing for a familial mutation was performed in 15% of our sample. In this subset of patients, 44% tested positive, and were given recommendations for medical management based on their results. For those

Table 4. Number of mutations detected based on cancer diagnosis.

| Cancer diagnosis                  | Total number of cancer diagnoses | Mutations identified | Number of deleterious | Number of likely | Number of VUS |
|----------------------------------|---------------------------------|----------------------|-----------------------|------------------|--------------|
| Breast                           | 400                             | BRCA-1 18            | –                     | 3                |              |
|                                  |                                 | BRCA-2 21            | 3                     | 3                |              |
|                                  |                                 | BRIP1 1              | –                     | –                |              |
| Ovary                            | 27                              | BRCA-1 4             | –                     | –                |              |
|                                  |                                 | BRCA2 1              | –                     | –                |              |
| Colorectal                       | 49                              | APC 1                | –                     | –                |              |
|                                  |                                 | MLH1 2               | –                     | –                |              |
|                                  |                                 | MYH –                | –                     | 1                |              |
|                                  |                                 | Mono-MYH 1           | –                     | –                |              |
|                                  |                                 | MSH2 1               | –                     | 1                |              |
|                                  |                                 | MSH6 1               | –                     | 2                |              |
|                                  |                                 | PMS2 –               | –                     | 1                |              |
|                                  |                                 | BRIP1 –              | –                     | 1                |              |
| Colon adenomas/polyps            | 60                              | APC 2                | –                     | 3                |              |
|                                  |                                 | MYH –                | –                     | 2                |              |
|                                  |                                 | Bi-MYH 1             | –                     | –                |              |
|                                  |                                 | Mono-MYH 2           | –                     | –                |              |
|                                  |                                 | MSH2 2               | 2                     | 2                | –            |
|                                  |                                 | MSH6 –               | –                     | 2                |              |
|                                  |                                 | PMS2 –               | –                     | 2                |              |
|                                  |                                 | BRCA2 –              | –                     | 1                |              |
| Desmoid tumors                   | 1                               | –                    | –                     | –                |              |
| Jejunum                          | 1                               | –                    | –                     | –                |              |
| Pancreas                         | 6                               | MSH2 1               | –                     | –                |              |
| Prostate                         | 3                               | BRCA2 –              | –                     | 1                |              |
| Endometrial/uterine              | 15                              | Mono-MYH 1           | –                     | –                |              |
|                                  |                                 | MSH2 –               | 1                     | –                |              |
| Renal pelvis                     | 2                               | MSH6 1               | –                     | –                |              |
| Fallopian tube                   | 3                               | BRCA1 1              | –                     | –                |              |
| Cervix                           | 5                               | MSH2 1               | –                     | –                |              |
| Melanoma                         | 7                               | MLH1 1               | –                     | –                |              |
| Thyroid                          | 4                               | –                    | –                     | –                |              |
| Bladder                          | 1                               | –                    | –                     | –                |              |
| Leukemia                         | 3                               | –                    | –                     | –                |              |
| Sarcoma                          | 1                               | BRCA1 1              | –                     | –                |              |
| Sebaceous                        | 3                               | MSH2 2               | –                     | –                |              |
| Other                            | 21                              | BRCA1 2              | –                     | –                |              |
|                                  |                                 | Mono-MYH 1           | –                     | –                |              |
|                                  |                                 | MSH2 –               | –                     | 1                |              |
| No cancer diagnosis              | 386                             | APC 4                | –                     | 1                |              |
|                                  |                                 | ATM –                | –                     | 1                |              |
|                                  |                                 | BRCA1 26             | –                     | –                |              |
|                                  |                                 | BRCA2 23             | –                     | 5                |              |
|                                  |                                 | BRIP1 –              | –                     | 1                |              |
|                                  |                                 | MLH1 1               | –                     | –                |              |
|                                  |                                 | Mono-MYH 2           | –                     | –                |              |
|                                  |                                 | MSH6 –               | –                     | 2                |              |
|                                  |                                 | MSH2 2               | –                     | –                |              |

\( N = \) total number of identified mutations and includes individuals with more than 1 mutation; 63 individuals reported more than 1 cancer diagnosis (55 reported 2 and 8 reported 3), and therefore the individual participant’s gene mutation may be represented within multiple cancer diagnoses.
individuals in the subset who did not have a familial mutation, the emotional and financial benefit of learning of these negative results and not needing additional medical intervention may be beneficial at both the individual and at the larger economic level.

In 2006, MA was the first state to enact the HCRA, followed by the National Affordable Care Act (ACA) signed into law 3/23/2010 with most provisions taking place on January 1, 2014. Although universal healthcare is mandatory in the state of MA, it seems clear that the state still has a significant population of underinsured individuals when it comes to genetic testing services. This study included over 900 participants who received services from 2009 to 2014. Updated data from 2016 indicates that over 1600 Massachusetts residents have now received services from the GIFTSS program, clearly demonstrating a need in our community. The ACA has a provision to offer “essential health benefits” for preventive and wellness services, guided by the US preventative Services Task Force. Genetic testing covered under this act includes testing for “BRCA-related Cancer”. These benefits do not extend to those with a diagnosis of cancer or more rare cancer syndromes.

Additionally, laws surrounding health insurance, specifically for those with federal insurance, vary from state to state and often impact the underserved [6]. Even with the ACA in place, certain private and public health plans do not cover services such as genetic testing. Some plans were grandfathered into the ACA and therefore, not required to meet current standards and recommendations of the United States Preventative Services Task Force (USPSTF) [19]. Government insurance programs have limitations on who can be covered for genetic testing and when that genetic testing can occur. For example, Medicare enrollees unaffected by cancer do not meet criteria for coverage of genetic testing [6]. Both the ACA and Medicare policy would have eliminated coverage for 386 individuals in our sample, 15% who had a clinically actionable gene mutation that may have direct relevance to cancer treatment and care for at-risk relatives. Therefore, without assistance through the GIFTSS program, these at-risk individuals and their families could have potentially missed the opportunity to know their cancer risk, which has individual, family, health care system, and societal implications.

Some private insurers place additional restrictions. For instance, genetic counseling by an approved genetic counselor is required prior to testing. This may limit access in rural or underserved communities where genetic counselors might not be available. Alternative models of providing cancer genetic counseling might be of benefit to at-risk individuals, such as through telegenetic counseling or video counseling. In a randomized trial, telegenetic counseling has been shown to be noninferior to in-person counseling, although it did lead to lower rates of genetic testing uptake [20]. Utilizing a novel method of genetic counseling might help leverage resources to bring qualified professionals into the community. Other research indicates that telegenetics is considered convenient by participants [21] and more cost effective compared to in-person counseling [22]. Video counseling has also been shown to be feasible and acceptable to patients [23, 24]. The importance of identifying new ways of providing genetic services to communities that serve individuals who are racially, ethnically, or socially diverse is exceedingly important given the lack of diversity in the current workforce of genetic counselors [25] and low rates of genetic testing referral in racial or ethnic minority groups [26]. Therefore, to continue to reach underserved communities, genetic counselors and other genetics clinicians should utilize different approaches to make genetic counseling convenient and accessible.

Furthermore, the results of genetic testing may lead to additional treatment, diagnostic, or prevention recommendations. Co-payments and deductibles for those services may prove to be prohibitive in pursuing treatment recommendations based on the results of the testing [27]. The full magnitude of potential that comes from genetic testing can only be realized if at-risk individuals, and their potentially at-risk relatives, can access lifesaving early detection and prevention resources. Future research should expand upon this work to further evaluate how at-risk individuals within this population are referred for and access follow-up care. It remains to be seen if assisting high-risk individuals in the MA community to access genetic testing can make a positive impact on cancer prevention and early detection in this population.

Limitations

Our study has some limitations that should be noted. First, the accuracy of information entered on laboratory test requisition forms could not be verified. Although the test requisition forms ask for patient characteristics including family history information, it is unclear as to how deliberate these are completed by referring health care providers. Second, we were unable to capture additional socioeconomic information because this was a secondary data analysis. Further, sociodemographic data were limited to what was included on the laboratory case report forms. Therefore, data such as work status, marital status, and other sociodemographic characteristics were not included. Finally, we were unable to identify the number of unique families included in our sample because data were de-identified and specific mutation information was not available. It is possible that multiple individuals from the
same family may have been included which may inflate the mutation rate.

**Conclusion**

The results from this study are useful in describing genetic testing outcomes in this high-risk underserved community. Future work is needed to evaluate mutation rates in diverse samples to present a more inclusive description of the landscape of hereditary cancer risk in the general population. Continued research efforts should be devoted to promoting access to genetic testing in the high-risk underserved community.

**Acknowledgments**

We acknowledge Myriad Genetics for providing access to the data associated with this study.

**Conflict of Interests**

None declared.

**References**

1. National Comprehensive Cancer Network (NCCN) 2016. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (accessed 14 August 2015).

2. National Comprehensive Cancer Network (NCCN) 2016. Genetic/Familial High-Risk Assessment: Colorectal. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (accessed 14 August 2015).

3. Cragun, D., D. Bonner, J. Kim, M. Akbari, S. Narod, A. Gomez-Fuego, et al. 2015. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. Breast Cancer Res. Treat. 151:169–176.

4. Pal, T., D. Bonner, D. Cragun, A. N. Monteiro, C. Phelan, L. Servais, et al. 2015. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer 121:4173–4180.

5. Olaya, W., P. Esquivel, J. H. Wong, J. W. Morgan, A. Freeberg, S. Roy-Chowdhury, et al. 2009. Disparities in BRCA testing: when insurance coverage is not a barrier. Am. J. Surg. 198:562–565.

6. Prince, A. E. 2015. Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. J. Law Biosci. 2:365–395.

7. Abbasi, J. 2016. Expert panel makes cancer moonshot funding recommendations. JAMA 316:1636.

8. Underhill, M. L., K. R. Habin, and K. M. Shannon. 2016. Perceptions of cancer risk, cause, and needs in participants from low socioeconomic background at risk for hereditary cancer. Behav. Med. 19:1–9.

9. Riley, B. D., J. O. Culver, C. Skrzynia, L. A. Senter, J. A. Peters, J. W. Costalas, et al. 2012. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J. Genet. Counsel. 21:151–161.

10. Caga-anan, E. C. F., L. Smith, R. R. Sharp, and J. D. Lantos. 2012. Testing children for adult-onset genetic diseases. Pediatrics 129:163–167.

11. Stokols, D. 1996. Translating social ecological theory into guidelines for community health promotion. Am. J. Health Promot. 10:282–298.

12. Komenaka, I. K., J. N. Nodora, L. Madlensky, L. M. Winton, M. A. Heberer, R. B. Schwab, et al. 2015. Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. J. Comm. Genetics 7:1–7.

13. Churpek, J. E., T. Walsh, Y. Zheng, Z. Moton, A. M. Thornton, M. K. Lee, et al. 2015. Inherited predisposition to breast cancer among African American women. Breast Cancer Res. Treat. 149:31–39.

14. Weitzel, J. N., J. Clague, A. Martir-Negron, R. Ogaz, J. Herzog, C. Ricker, et al. 2013. Prevalence and type of BRCA mutations in hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the clinical cancer genetics community research network. J. Clin. Oncol. 31:210–216.

15. John, E. M., A. Miron, G. Gong, A. I. Phipps, A. Felberg, F. P. Li, et al. 2007. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876.

16. Weitzel, J. N., V. Lagos, K. R. Blazer, R. Nelson, C. Ricker, J. Herzog, et al. 2005. Prevalence of BRCA mutations and founder effect in high-risk hispanic families. Cancer Epidemiol. Biomark. Prev. 14:1666–1671.

17. El-Masry, M., C. Ricker, D. Spicer, and D. Tripathy. Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in an underserved population. Paper presented at: ASCO Annual Meeting Proceedings 2011.

18. Lynch, F., K. L. Smith, J. Stein, T. DeMarco, Y. Wang, H. Wang, et al. 2015. Deleterious BRCA1/2 mutations in an urban population of Black women. Breast Cancer Res. Treat. 153:201–209.

19. Seiler, N., M.-B. Malcarney, K. Horton, and S. Dafflitto. 2014. Coverage of clinical preventive services under the affordable care act: from law to access. Public Health Rep. 129:526–532.

20. Schwartz, M. D., H. B. Valdimarsdottir, B. N. Peshkin, J. Mandelblatt, R. Nusbaum, A.-T. Huang, et al. 2014. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J. Clin. Oncol. 32:618–626.
21. Peshkin, B. N., S. Kelly, R. H. Nusbaum, M. Similuk, T. A. DeMarco, G. W. Hooker, et al. 2015. Patient perceptions of telephone vs. in-person BRCA1/BRCA2 genetic counseling. J. Genet. Counsel. 25:1–11.
22. Buchanan, A. H., S. K. Datta, C. S. Skinner, G. P. Hollowell, H. F. Beresford, T. Freeland, et al. 2015. Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance. J. Genet. Counsel. 24:961–970.
23. Bradbury, A., L. Patrick-Miller, D. Harris, E. Stevens, B. Egleston, K. Smith, et al. 2016. Utilizing remote real-time videoconferencing to expand access to cancer genetic services in community practices: a multicenter feasibility study. J. Med. Inter. Res. 18:e23.
24. Zilliacus, E. M., B. Meiser, E. A. Lobb, P. J. Kelly, K. Barlow-Stewart, J. A. Kirk, et al. 2011. Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling? Genet. Med. 13:933–941.
25. Schoonveld, K. C., P. M. Veach, and B. S. LeRoy. 2007. What is it like to be in the minority? Ethnic and gender diversity in the genetic counseling profession. J. Genet. Counsel. 16:53–69.
26. Cragun, D., A. Weidner, C. Lewis, D. Bonner, J. Kim, S. T. Vadaparampil, et al. 2017. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. E-pub ahead of print.
27. Daly, B., and O.I. Olopade. 2015. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J. Clin. 65:221–238.